Chronic kidney disease, stage 5 (ESRD). Chronic kidney disease, stage 5
Conditions
Interventions
Intervention group: 54 selected dialysis patients, after a training session and obtaining consent, are treated with 50,000 vitamin D tablets made by Dana Tabriz-Iran company, one tablet per week after
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Informed consent to enter the study A history of regular hemodialysis for at least 12 weeks Not suffering from malignant and active blood diseases No history of major surgery in the last 6 months No smoking
Exclusion criteria
Exclusion criteria: Lack of consent to enter the research Recent heavy bleeding Getting malignant diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of dialysis patients with anemia. Timepoint: Measurement of blood hemoglobin at the beginning of the study and 90 days after starting vitamin D tablets. Method of measurement: using spectrophotometer (LKB, UK) and microhematocrit (made in Germany) devices. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin number after taking vitamin D tablets. Timepoint: Measurement of blood hemoglobin at the beginning of the study and 90 days after starting vitamin D tablets. Method of measurement: using spectrophotometer (LKB, UK) and microhematocrit (made in Germany) devices. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ali Sadouq Abbasian
Arak University of Medical Sciences
Outcome results
None listed